{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000921","form_type":"8-K","ticker":"ITGR","cik":"0001114483","company_name":"Integer Holdings Corp","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.556627+00:00","generated_at":"2026-05-16T01:39:15.284311+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integer reports Q4 adjusted EPS $1.76, 23% YoY growth; full year adjusted EPS $6.40, up 21%","bullets":["Q4 sales $472M (+5% YoY); GAAP EPS $1.38, adjusted EPS $1.76 (+23%).","FY25 sales $1.854B (+8%); GAAP EPS $2.89 (-15%), adjusted EPS $6.40 (+21%).","Cardio & Vascular sales grew 11% Q4; Cardiac Rhythm Mgmt & Neuromodulation down 2% Q4.","Initiates $50M accelerated share repurchase under existing $200M board authorization.","2026 outlook: sales $1.826B-$1.876B (flat YoY); adjusted EPS $6.29-$6.78 (down 2% to up 6%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000921","json":"https://secwatch.observer/filing/0001171843-26-000921.json","markdown":"https://secwatch.observer/filing/0001171843-26-000921.md","text":"https://secwatch.observer/filing/0001171843-26-000921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114483/000117184326000921/0001171843-26-000921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114483/000117184326000921/f8k_021926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:39:15.284311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}